Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
YF438 is an HDAC inhibitor, potentially inhibiting tumor growth and metastasis (PMID: 33985974).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|YF438||YF-438|YF 438||HDAC Inhibitor 42||YF438 is an HDAC inhibitor, potentially inhibiting tumor growth and metastasis (PMID: 33985974).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MDM2 C464A||triple-receptor negative breast cancer||no benefit||YF438||Preclinical - Cell culture||Actionable||In a preclinical study, YF438 treatment did not inhibit cell growth or induce apoptosis in triple-negative breast cancer cells expressing MDM2 C464A in culture (PMID: 33985974).||33985974|
|MDM2 positive||triple-receptor negative breast cancer||sensitive||YF438||Preclinical||Actionable||In a preclinical study, YF438 treatment inhibited H3 and H4 acetylation, promoted Mdm2 degradation, led to growth inhibition and increased apoptosis in triple-negative breast cancer cell lines in culture, and reduced tumor growth and metastasis, extended overall survival in an orthotopic autograft model (PMID: 33985974).||33985974|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|